Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in 2025.

ImmunoPrecise Antibodies Ltd. (IPA) has developed a new class of GLP-1 therapies entirely through artificial intelligence, designed to enhance efficacy, safety, therapy longevity, and patient ...

Coherus markets LOQTORZI® (toripalimab-tpzi), a novel next-generation PD-1 inhibitor, and UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta. In December 2024, Coherus announced the planned ...

In return for these rights, ArriVent will pay Lepu a one-time down payment and near-term milestone payments amounting to ...

In a recent study, scientists have introduced an innovative imaging technique that provides an unparalleled view of the bone marrow's intricate ...

Antivenoms, or antivenins, are life-saving medicines used to treat snakebites. They are produced by injecting small amounts ...

Danish team led by Nobel Prize winner David Baker has designed synthetic molecules that protect mice against cobra toxins.

Dr. Imbert brings 25 years of strategic clinical to commercial-stage manufacturing and drug development experienceSOUTH SAN FRANCISCO, Calif., ...

USANA Health Sciences, Inc., a global leader in cellular nutrition, is proud to announce that Dr. Kathryn Armstrong, Ph.D., ...

Discover the potential of macrocycles in drug discovery: flexible, cell-permeable molecules targeting undruggable proteins.

A new wearable device using graphene sensors can accurately measure biomarkers in sweat, enabling real-time, needle-free ...

Researchers at the University of Oxford are part of a team that has received a grant to develop vaccines against ...